Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate

Background: Sorafenib is the first oral therapeutic agent to show the activity against human hepatocellular carcinoma. Sorafenib leads to severe toxicity due to the multiple-dose regimen. Reducing the overall dose of sorafenib through injectable dosage form to release sustainably is of therapeutical...

Descripción completa

Detalles Bibliográficos
Autores principales: Moni, Sivakumar S., Alam, Mohammad F., Safhi, Mohammed M., Sultan, Muhammad H., Makeen, Hafiz A., Elmobark, Mohamed E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509770/
https://www.ncbi.nlm.nih.gov/pubmed/31886748
http://dx.doi.org/10.2174/1389201021666191230124041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509770/
https://www.ncbi.nlm.nih.gov/pubmed/31886748
http://dx.doi.org/10.2174/1389201021666191230124041

Ejemplares similares